US Pharma MarketingArgenx
Argenx halts Ph3 Sjögren Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug…
Argenx on Thursday reported one success and one setback in its autoimmune disease pipeline, sending its shares tumbling.
The Belgian-Dutch pharma said it is shuttering a Phase 3 trial of its ...
Source: Endpoints News